In a highly challenging case, a 55-year-old woman suffering from a complex renal tumor located dangerously close to the ...
When the kidneys are damaged—after surgery, cardiac arrest, or as a side effect of certain medications—doctors often face one ...
P3 Health Partners Inc. (NASDAQ: PIII) Q3 2025 Earnings Call Transcript November 14, 2025 P3 Health Partners Inc. misses on ...
1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...
Third quarter performance driven by strong portfolio royalty revenue growth of 47%2025 full year revenue guidance increased to $225 million - ...
Three years ago, the FDA found so many violations at a Nephron Pharmaceuticals manufacturing facility that the U.S. regulator admitted in a warning letter the issues were so numerous they couldn’t all ...
Despite multiple warnings from the Food and Drug Administration about its manufacturing processes, Nephron Pharmaceuticals, one of the largest employers in Lexington, has continued to face federal ...
According to researcher Anne Robertson, the bladder is not considered a particularly glamorous organ, despite hosting many of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback